Naringenin derivatives as anti-atherogenic agents

Bioorganic and Medicinal Chemistry Letters

Volumn 13, Issue 22, 2003, Pages 3901-3903

  Lee, Sangku ^a   Lee, Chul Ho ^a   Moon, Surk Sik ^b   Kim, Eungsoo ^a   Kim, Chul Tae ^a   Kim, Bang Hyun ^a   Bok, Song Hae ^a   Jeong, Tae Sook ^a  

^a Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^b Kongju National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

NARINGENIN; NARINGENIN 7 O CETYL ETHER; NARINGENIN 7 O OLEIC ESTER; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROGENESIS; CHOLESTEROL INTAKE; CONTROLLED STUDY; DRUG ACTIVITY; EVALUATION; NONHUMAN; RABBIT;

ORYCTOLAGUS CUNICULUS;

EID: 0242380244     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2003.09.009     Document Type: Article

References (12)

1. Middleton, E., Jr.; Kandaswami, C. In The Flavonoids: Advances in Research Since 1986; Harborne, J. B., Ed.; Chapman and Hall: London, 1994; p 619.
2. Miura S., Watanabe J., Sano M., Tomita T., Osawa T., Hara Y., Tomita I. Biol. Pharm. Bull. 18:1995;1.
3. Matsuo N., Yamada K., Yamashita K., Shoji K., Mori M., Sugano M. In Vitro Cell Dev. Biol. 32:1996;340.
4. Hamiltonmiller J.M.T. Antimicrob. Agent Chemother. 39:1995;2375.
5. Shivji G.M., Zielinska E., Kondo S., Mukhtar H., Sander D.N. J. Invest. Dermatol. 106:1996;787.
6. Yamada J., Tomita Y. Biosci. Biotech. Biochem. 58:1994;2197.
7. Han C. Cancer Lett. 114:1997;153.
8. Lee C.-H., Jeong T.-S., Choi Y.-K., Hyun B.-H., Oh G.-T., Kim E.-H., Kim J.-R., Han J.-I., Bok S.-H. Biochem. Biophys. Res. Commun. 284:2001;681.
9. Lee M.-K., Moon S.-S., Lee S.-E., Bok S.-H., Jeong T.-S., Park Y.B., Choi M.-S. Bioorg. Med. Chem. 11:2003;393.
10. 3) δ 197.2, 171.4, 163.1, 162.3, 158.3, 156.3, 130.0, 129.7, 129.6, 127.8, 115.6, 106.1, 103.1, 101.7, 79.0, 43.3, 34.4, 31.9, 29.8, 29.7, 29.5, 29.3, 29.2, 29.1, 29.0, 28.9, 27.2, 27.1, 24.8, 22.7, 14.2; 1D NOESY: NOE contacts were observed between H (6.28 and 6.26 ppm) and H (2.53 ppm).
11. 5 497.3267).
12. Male New Zealand White (NZW) rabbits weighing between 2.4 and 2.5 kg at the age of 3 months were used in the experiment. The rabbits were divided into three groups, which were supplemented with a 1% cholesterol diet (RC4, Oriental Yeast Co. Ltd, Tokyo, Japan; n=10), or a 1% cholesterol diet containing either 0.1% 2 (n=10) or 0.1% 3 (n=10) for 8 weeks. All rabbits were individually caged and maintained in a controlled facility at 20±2 °C , relative humidity (55±5%) and a strict 12 h light/dark cycle. First, for the analysis of plasma lipids, the blood samples (3 mL), with ethylenediamine- tetraacetic acid (EDTA) as an anticoagulant, were obtained from the marginal vein of the ear, and centrifuged at 8000g for 10 min. Collected plasma was analyzed in an automatic blood chemical analyzer (Hitachi 7020, Japan) and the plasma concentrations of total cholesterol, HDL-cholesterol, and triglyceride obtained (Table 1). Then, for the evaluation of aortic fatty streak lesions, all rabbits were anesthetized with thiopental sodium (Choongwae Pharma Co., Seoul, Korea) and sacrificed by exsanguinations from the femoral artery. Immediately after opening the thoracic cavity, the aorta was excised, and adventitial tissue grossly adhering to the aorta removed. The aorta was then dissected longitudinally. The portion, a segment between the first and the sixth intercostal arteries, was fixed in 10% neutral buffered formalin for 1 day. The aorta was then placed in absolute propylene glycol for 2 min and stained with oil red O for 4 h. After washing, the extent of the oil red O-positive area was measured and expressed as a percentage of the internal surface using a computer-assisted morphometry system (Image Pro Plus, MD, USA).